341 related articles for article (PubMed ID: 22761000)
1. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
[TBL] [Abstract][Full Text] [Related]
2. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
3. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
[TBL] [Abstract][Full Text] [Related]
4. Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates.
Wen D; Liu A; Chen F; Yang J; Dai R
J Appl Toxicol; 2012 Oct; 32(10):834-42. PubMed ID: 22744888
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
[TBL] [Abstract][Full Text] [Related]
6. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
7. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
[TBL] [Abstract][Full Text] [Related]
8. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
[TBL] [Abstract][Full Text] [Related]
9. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
Li Q; Jørgensen FS; Oprea T; Brunak S; Taboureau O
Mol Pharm; 2008; 5(1):117-27. PubMed ID: 18197627
[TBL] [Abstract][Full Text] [Related]
10. Impaired Inactivation of L-Type Ca2+ Current as a Potential Mechanism for Variable Arrhythmogenic Liability of HERG K+ Channel Blocking Drugs.
Kim JG; Sung DJ; Kim HJ; Park SW; Won KJ; Kim B; Shin HC; Kim KS; Leem CH; Zhang YH; Cho H; Bae YM
PLoS One; 2016; 11(3):e0149198. PubMed ID: 26930604
[TBL] [Abstract][Full Text] [Related]
11. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
12. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
13. A binary QSAR model for classification of hERG potassium channel blockers.
Thai KM; Ecker GF
Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
[TBL] [Abstract][Full Text] [Related]
14. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine.
Choi SY; Koh YS; Jo SH
J Pharmacol Exp Ther; 2005 May; 313(2):888-95. PubMed ID: 15722405
[TBL] [Abstract][Full Text] [Related]
16. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
17. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
18. Computational investigations of hERG channel blockers: New insights and current predictive models.
Villoutreix BO; Taboureau O
Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
[TBL] [Abstract][Full Text] [Related]
19. In silico prediction of hERG inhibition.
Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
[TBL] [Abstract][Full Text] [Related]
20. Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic.
Kang J; Compton DR; Vaz RJ; Rampe D
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1133-7. PubMed ID: 27530870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]